Comorbidities cluster with impaired functional capacities and depressive mood and predict adverse outcome in older patients with hematological malignancies

References

• Bron D, Ades L, Fulop T, SWG ETFiHE, et al. Aging and blood disorders: new perspectives, new challenges. Haematologica. 2015;100(4):415–417.
   PubMed Web of Science ®Google Scholar
• Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131(5):515–524.
   PubMed Web of Science ®Google Scholar
• Larocca A, Dold SM, Zweegman S, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32(8):1697–1712.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology Summary. J Oncol Pract. 2018;14(7):442–446.
   PubMed Web of Science ®Google Scholar
• Stauder R, Moser K, Holzner B, et al. Six independent domains are defined by geriatric assessment in elderly cancer patients. Crit Rev Oncol Hematol. 2010;74(2):97–105.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Wells RA, Zhu N, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174(1):88–101.
   PubMed Web of Science ®Google Scholar
• Chaïbi P, Magné N, Breton S, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol. 2011;79(3):302–307.
   PubMed Web of Science ®Google Scholar
• Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114–119.
   PubMed Web of Science ®Google Scholar
• Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol. 2015;6(4):272–279.
   PubMed Web of Science ®Google Scholar
• Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165(4):489–496.
   PubMed Web of Science ®Google Scholar
• Martínez C, Jorge AS, Pereira A, et al. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years. Ann Hematol. 2017;96(1):9–16.
   PubMed Web of Science ®Google Scholar
• Gentile M, Zirlik K, Ciolli S, et al. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. Eur J Cancer. 2016;60:154–165.
   PubMed Web of Science ®Google Scholar
• Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729–732.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Sasaki K, Montalban-Bravo G, et al. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019;125(13):2233–2241.
   PubMed Web of Science ®Google Scholar
• Dorsheimer L, Assmus B, Rasper T, et al. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol. 2019;4(1):25–33.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–121.
   PubMed Web of Science ®Google Scholar
• Libby P, Jaiswal S, Lin AE, et al. CHIPping away at the pathogenesis of heart failure. JAMA Cardiol. 2019;4(1):5.
   PubMed Web of Science ®Google Scholar
• Sellar RS, Jaiswal S, Ebert BL. Predicting progression to AML. Nat Med. 2018;24(7):904–906.
   PubMed Web of Science ®Google Scholar
• Bammer C, Sperr WR, Kemmler G, et al. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J Geriatr Oncol. 2014;5(3):299–306.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237–248.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453–471.
   PubMed Web of Science ®Google Scholar
• de Groot V, Beckerman H, Lankhorst GJ, et al. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003;56(3):221–229.
   PubMed Web of Science ®Google Scholar
• Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402–408.e1.
   PubMed Web of Science ®Google Scholar
• Stauder R, Nösslinger T, Pfeilstöcker M, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6(9):927–934.
   PubMedGoogle Scholar
• Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93(6):1031–1040.
   PubMed Web of Science ®Google Scholar
• Tawfik B, Pardee TS, Isom S, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016;7(1):24–31.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Halene S, et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009;33(12):1594–1598.
   PubMed Web of Science ®Google Scholar
• Savic A, Kvrgic V, Rajic N, et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36(4):479–482.
   PubMed Web of Science ®Google Scholar
• Grønberg BH, Sundstrøm S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010;46(12):2225–2234.
   PubMed Web of Science ®Google Scholar
• Ngeow J, Leong SS, Gao F, et al. Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. Crit Rev Oncol Hematol. 2010;76(1):53–60.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Østgård LS, Nørgaard JM, Sengeløv H, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia. 2015;29(3):548–555.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Bowen D, Venkat C, Slager SL, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139(2):255–264.
   PubMed Web of Science ®Google Scholar
• Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494–502.
   PubMed Web of Science ®Google Scholar
• Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136–147.
   PubMedGoogle Scholar
• Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–1392.
   PubMed Web of Science ®Google Scholar
• Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–495.
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505–522.
   PubMed Web of Science ®Google Scholar
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842–847.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Wass M, Hitz F, Schaffrath J, et al. Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia. PLoS One. 2016;11(10):e0164587.
   PubMed Web of Science ®Google Scholar
• Wedding U, Röhrig B, Klippstein A, et al. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol. 2007;133(12):945–950.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196–204.
   PubMed Web of Science ®Google Scholar
• Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and mortality in older adults: A systematic review and meta-analysis. Arch Gerontol Geriatr. 2016;67:130–138.
   PubMed Web of Science ®Google Scholar
• Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29.
   PubMedGoogle Scholar
• Limat S, Daguindau E, Cahn JY, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39(2):168–174.
   PubMed Web of Science ®Google Scholar
• Novosyadlyy R, Leroith D. Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci. 2012;67(6):640–651.
   PubMed Web of Science ®Google Scholar
• Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–2764.
   PubMed Web of Science ®Google Scholar